Silence Therapeutics PLC · NASDAQ:SLN

Silence Therapeutics — FY2019 Earnings Presentation

8 slides from Silence Therapeutics's earnings presentation, Apr 14, 2020

  1. Slide 1: Silence Therapeutics FY19 Results call

    Silence Therapeutics FY19 Results call April 14 2020 © Silence Therapeutics 2019 CONFIDENTIAL 1

  2. Slide 2: Disclaimer

    Disclaimer The information contained in this presentation is being supplied and communicated to you solely for your Safe Harbour statement: this presentation may contain forward-looking statements that reflect the Company’s information and may not be reproduced, further distributed to any other pers

  3. Slide 3: Agenda

    Agenda • Opening remarks Iain Ross, Executive Chairman • FY19 Results Dr Rob Quinn, Chief Financial Officer • Q&A All participants Iain Ross Giles Campion Rob Quinn John Strafford © Silence Therapeutics 2020 3

  4. Slide 4: Full Year Results – Highlights

    Full Year Results – Highlights Operational Highlights Q1 2020 progress • Continued advancement of our two late stage preclinical programmes (SLN360 and • CEO recruitment progressing well with SLN124) announcement possible as soon as mid-2020 • Research and collaboration agreement with Mallinckrodt P

  5. Slide 5: Financial results

    Financial results • Revenue recognised from Alnylam royalty (£73k) and Mallinckrodt collaboration (£171k). Revenue recognition Income statement (GBP '000) 2019 2018 relating to Mallinckrodt significantly less than cash received ($20m upfront and $2m milestone) as revenue is recognised over the cours

  6. Slide 6: Collaboration with AstraZeneca for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases

    Collaboration with AstraZeneca for the Treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases • Research, Collaboration, Option and Licence agreement to discover and develop RNA interference therapeutics for the treatment of serious diseases. > Draws on Silence’s extensive experience

  7. Slide 7: Silence Therapeutics - Summary

    Silence Therapeutics - Summary > Reproducible, proprietary gene silencing (RNAi) therapeutics platform, rapidly generating Valuable Platform internal pipeline and out-licensing options. Platform validated through collaborations with HQ in London AstraZeneca, Mallinckrodt and Takeda > SLN360 (CVD wit

  8. Slide 8: © Silence Therapeutics 2020

    © Silence Therapeutics 2020 8

Silence Therapeutics — FY2019 Earnings Presentation on 6ix